Treatment Of Impetigo With Topical SB-275833 Ointment, 1% Versus Topical Placebo Ointment

Study Results

Results pending

The study team has not published outcome measurements, participant flow, or safety data for this trial yet. Check back later for updates.

Basic Information

Get a concise snapshot of the trial, including recruitment status, study phase, enrollment targets, and key timeline milestones.

Recruitment Status

COMPLETED

Clinical Phase

PHASE3

Total Enrollment

210 participants

Study Classification

INTERVENTIONAL

Study Start Date

2005-04-30

Study Completion Date

2006-01-31

Brief Summary

Review the sponsor-provided synopsis that highlights what the study is about and why it is being conducted.

The goal of this study is to determine if topical SB-275833 ointment, 1% is more effective than a placebo ointment in the treatment of primary impetigo.

Related Clinical Trials

Explore similar clinical trials based on study characteristics and research focus.

To Assess the Efficacy and Safety of INCB054707 in Participants With Hidradenitis Suppurativa

NCT04476043

Hidradenitis Suppurativa Acne Inversa

COMPLETED PHASE2

A Multi-Center Study to Evaluate the Efficacy and Safety of KX2-391 Ointment 1% on AK on Face or Scalp

NCT03285477

Actinic Keratoses

COMPLETED PHASE3

Safety and Efficacy Study of AM001 Cream in the Treatment of Actinic Keratosis

NCT03210740

Actinic Keratosis

COMPLETED PHASE2

A Multi-center Study to Evaluate the Safety and Efficacy of PEP005 (Ingenol Mebutate) Gel, When Used to Treat Actinic Keratoses on Non-head Locations (Trunk and Extremities)

NCT00917306

Actinic Keratosis

COMPLETED PHASE3

A Proof-of-Concept Study of Topical AC-203 in Patients With Bullous Pemphigoid

NCT03286582

Bullous Pemphigoid

TERMINATED PHASE2

Detailed Description

Dive into the extended narrative that explains the scientific background, objectives, and procedures in greater depth.

Conditions

See the medical conditions and disease areas that this research is targeting or investigating.

Impetigo

Study Design

Understand how the trial is structured, including allocation methods, masking strategies, primary purpose, and other design elements.

Allocation Method

RANDOMIZED

Primary Study Purpose

TREATMENT

Blinding Strategy

DOUBLE

Interventions

Learn about the drugs, procedures, or behavioral strategies being tested and how they are applied within this trial.

SB-275833 ointment, 1%

Intervention Type DRUG

Other Intervention Names

Discover alternative or legacy names that may be used to describe the listed interventions across different sources.

SB-275833 ointment 1%

Eligibility Criteria

Check the participation requirements, including inclusion and exclusion rules, age limits, and whether healthy volunteers are accepted.

Inclusion Criteria

* Must have primary impetigo with total lesion area being 100 square centimeters or less.
* Women who could bear children must have a negative urine pregnancy test and agree to either abstain from sexual intercourse or the use of specific effective contraceptive measures.

Exclusion Criteria

* Any signs and symptoms of systemic infection.
* Any serious underlying disease that could be imminently life threatening.

Minimum Eligible Age

9 Months

Eligible Sex

ALL

Accepts Healthy Volunteers

No

Responsible Party

Identify the individual or organization who holds primary responsibility for the study information submitted to regulators.

Responsibility Role SPONSOR

Principal Investigators

Learn about the lead researchers overseeing the trial and their institutional affiliations.

GSK Clinical Trials

Role: STUDY_DIRECTOR

GlaxoSmithKline

Locations

Explore where the study is taking place and check the recruitment status at each participating site.

GSK Investigational Site

Bangalore, , India

Site Status

GSK Investigational Site

Hyderabad, , India

Site Status

GSK Investigational Site

Rome, Lazio, Italy

Site Status

GSK Investigational Site

Zapopan, Jalisco, Jalisco, Mexico

Site Status

GSK Investigational Site

Mexico City, , Mexico

Site Status

GSK Investigational Site

Beek en Donk, , Netherlands

Site Status

GSK Investigational Site

Deurne, , Netherlands

Site Status

GSK Investigational Site

Ermelo, , Netherlands

Site Status

GSK Investigational Site

Gouda, , Netherlands

Site Status

GSK Investigational Site

Musselkanaal, , Netherlands

Site Status

GSK Investigational Site

Musselkanaal, , Netherlands

Site Status

GSK Investigational Site

Nijmegen, , Netherlands

Site Status

GSK Investigational Site

Nijverdal, , Netherlands

Site Status

GSK Investigational Site

Roelofarendsveen, , Netherlands

Site Status

GSK Investigational Site

Rotterdam, , Netherlands

Site Status

GSK Investigational Site

Rotterdam, , Netherlands

Site Status

GSK Investigational Site

Soerendonk, , Netherlands

Site Status

GSK Investigational Site

Woerden, , Netherlands

Site Status

GSK Investigational Site

Zieuwent, , Netherlands

Site Status

GSK Investigational Site

Zwijndrecht, , Netherlands

Site Status

GSK Investigational Site

Callao, Provincia Constitucional del Callao, Peru

Site Status

GSK Investigational Site

Lima, , Peru

Site Status

Countries

Review the countries where the study has at least one active or historical site.

India Italy Mexico Netherlands Peru

Study Documents

Access uploaded study-related documents such as protocols, statistical analysis plans, or lay summaries.